232 related articles for article (PubMed ID: 19043454)
21. Characterization of the zinc finger proteins ZMYM2 and ZMYM4 as novel B-MYB binding proteins.
Cibis H; Biyanee A; Dörner W; Mootz HD; Klempnauer KH
Sci Rep; 2020 May; 10(1):8390. PubMed ID: 32439918
[TBL] [Abstract][Full Text] [Related]
22. Estrogen-induced changes in IGF-I, Myb family and MAP kinase pathway genes in human uterine leiomyoma and normal uterine smooth muscle cell lines.
Swartz CD; Afshari CA; Yu L; Hall KE; Dixon D
Mol Hum Reprod; 2005 Jun; 11(6):441-50. PubMed ID: 15879465
[TBL] [Abstract][Full Text] [Related]
23. B-Myb regulates snail expression to promote epithelial-to-mesenchymal transition and invasion of breast cancer cell.
Tao D; Pan Y; Jiang G; Lu H; Zheng S; Lin H; Cao F
Med Oncol; 2015 Jan; 32(1):412. PubMed ID: 25502082
[TBL] [Abstract][Full Text] [Related]
24. Posttranscriptional regulation of the c-myb proto-oncogene in estrogen receptor-positive breast cancer cells.
Gudas JM; Klein RC; Oka M; Cowan KH
Clin Cancer Res; 1995 Feb; 1(2):235-43. PubMed ID: 9815978
[TBL] [Abstract][Full Text] [Related]
25. Adenovirus-mediated human topoisomerase IIalpha gene transfer increases the sensitivity of etoposide-resistant human and mouse breast cancer cells.
Asano T; Kleinerman ES; Zwelling LA; Zhou Z; Fukunaga Y
Acta Oncol; 2005; 44(3):240-7. PubMed ID: 16076696
[TBL] [Abstract][Full Text] [Related]
26. Altered topoisomerase IIalpha and multidrug resistance-associated protein levels during drug selection: adaptations to increasing drug pressure.
Matsumoto Y; Takano H; Nagao S; Fojo T
Jpn J Cancer Res; 2001 Sep; 92(9):968-74. PubMed ID: 11572765
[TBL] [Abstract][Full Text] [Related]
27. Mybl2 expression is under genetic control and contributes to determine a hepatocellular carcinoma susceptible phenotype.
Frau M; Ladu S; Calvisi DF; Simile MM; Bonelli P; Daino L; Tomasi ML; Seddaiu MA; Feo F; Pascale RM
J Hepatol; 2011 Jul; 55(1):111-9. PubMed ID: 21419759
[TBL] [Abstract][Full Text] [Related]
28. Distinct changes in gene expression induced by A-Myb, B-Myb and c-Myb proteins.
Rushton JJ; Davis LM; Lei W; Mo X; Leutz A; Ness SA
Oncogene; 2003 Jan; 22(2):308-13. PubMed ID: 12527900
[TBL] [Abstract][Full Text] [Related]
29. Expression of insulin-like growth factor-binding protein 5 in neuroblastoma cells is regulated at the transcriptional level by c-Myb and B-Myb via direct and indirect mechanisms.
Tanno B; Negroni A; Vitali R; Pirozzoli MC; Cesi V; Mancini C; Calabretta B; Raschellà G
J Biol Chem; 2002 Jun; 277(26):23172-80. PubMed ID: 11973331
[TBL] [Abstract][Full Text] [Related]
30. B-Myb promotes S-phase independently of its sequence-specific DNA binding activity and interacts with polymerase delta-interacting protein 1 (Pdip1).
Werwein E; Schmedt T; Hoffmann H; Usadel C; Obermann N; Singer JD; Klempnauer KH
Cell Cycle; 2012 Nov; 11(21):4047-58. PubMed ID: 23032261
[TBL] [Abstract][Full Text] [Related]
31. Gene expression patterns associated with p53 status in breast cancer.
Troester MA; Herschkowitz JI; Oh DS; He X; Hoadley KA; Barbier CS; Perou CM
BMC Cancer; 2006 Dec; 6():276. PubMed ID: 17150101
[TBL] [Abstract][Full Text] [Related]
32. Direct transactivation of the anti-apoptotic gene apolipoprotein J (clusterin) by B-MYB.
Cervellera M; Raschella G; Santilli G; Tanno B; Ventura A; Mancini C; Sevignani C; Calabretta B; Sala A
J Biol Chem; 2000 Jul; 275(28):21055-60. PubMed ID: 10770937
[TBL] [Abstract][Full Text] [Related]
33. B-Myb represses trans-activation of the Col5A2 collagen promoter indirectly via inhibition of binding of factors interacting with positive elements within the first exon.
Kypreos KE; Marhamati DJ; Sonenshein GE
Matrix Biol; 1999 Jun; 18(3):275-85. PubMed ID: 10429946
[TBL] [Abstract][Full Text] [Related]
34. Inhibition of cyclin A/Cdk2 phosphorylation impairs B-Myb transactivation function without affecting interactions with DNA or the CBP coactivator.
Bessa M; Saville MK; Watson RJ
Oncogene; 2001 Jun; 20(26):3376-86. PubMed ID: 11423988
[TBL] [Abstract][Full Text] [Related]
35. B-Myb Induces APOBEC3B Expression Leading to Somatic Mutation in Multiple Cancers.
Chou WC; Chen WT; Hsiung CN; Hu LY; Yu JC; Hsu HM; Shen CY
Sci Rep; 2017 Mar; 7():44089. PubMed ID: 28276478
[TBL] [Abstract][Full Text] [Related]
36. Gene expression profiling of breast cancer patients treated with docetaxel, doxorubicin, and cyclophosphamide within the GEPARTRIO trial: HER-2, but not topoisomerase II alpha and microtubule-associated protein tau, is highly predictive of tumor response.
Rody A; Karn T; Gätje R; Ahr A; Solbach C; Kourtis K; Munnes M; Loibl S; Kissler S; Ruckhäberle E; Holtrich U; von Minckwitz G; Kaufmann M
Breast; 2007 Feb; 16(1):86-93. PubMed ID: 17010609
[TBL] [Abstract][Full Text] [Related]
37. ADA3 regulates normal and tumor mammary epithelial cell proliferation through c-MYC.
Griffin NI; Sharma G; Zhao X; Mirza S; Srivastava S; Dave BJ; Aleskandarany M; Rakha E; Mohibi S; Band H; Band V
Breast Cancer Res; 2016 Nov; 18(1):113. PubMed ID: 27852327
[TBL] [Abstract][Full Text] [Related]
38. Regulation of the cell cycle by B-Myb.
Bessa M; Joaquin M; Tavner F; Saville MK; Watson RJ
Blood Cells Mol Dis; 2001; 27(2):416-21. PubMed ID: 11259164
[TBL] [Abstract][Full Text] [Related]
39. MYBL2 Is Targeted by miR-143-3p and Regulates Breast Cancer Cell Proliferation and Apoptosis.
Chen J; Chen X
Oncol Res; 2018 Jul; 26(6):913-922. PubMed ID: 29268817
[TBL] [Abstract][Full Text] [Related]
40. Expression of topoisomerase II-α in triple negative breast cancer.
Mrklić I; Pogorelić Z; Ćapkun V; Tomić S
Appl Immunohistochem Mol Morphol; 2014 Mar; 22(3):182-7. PubMed ID: 23702653
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
